Curaleaf Holdings (CURLF) Total Non-Current Liabilities (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Total Non-Current Liabilities of $1.3 billion for Q4 2025, up 1.85% year-on-year from $1.3 billion in Q4 2024, and up 1.85% on a QoQ basis from $1.3 billion in Q4 2024.
Curaleaf Holdings (CURLF) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Total Non-Current Liabilities for 7 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 1.85% year-over-year to $1.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 billion (up 1.85% YoY) and the FY2025 annual result came in at $1.3 billion, up 1.85% from the prior year.
- Total Non-Current Liabilities rose to $1.3 billion in Q4 2025 per CURLF's latest filing, from $1.3 billion in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for CURLF reached as high as $2.0 billion in Q3 2023 and fell as low as -$6.6 billion in Q1 2022.
- A 5-year average of $904.4 million and a median of $1.4 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- The largest YoY upside for Total Non-Current Liabilities was 24165.83% in 2022 against a maximum downside of 715.47% in 2022.
- Year by year, Total Non-Current Liabilities stood at $4.2 million in 2021, then jumped by 24165.83% to $1.0 billion in 2022, then surged by 33.87% to $1.4 billion in 2023, then decreased by 4.82% to $1.3 billion in 2024, then rose by 1.85% to $1.3 billion in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.3 billion, $1.3 billion, and $2.0 billion for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Sep 30, 2024 | 1.99 Bn |
| Jun 30, 2024 | 1.97 Bn |
| Dec 31, 2023 | 1.35 Bn |
| Sep 30, 2023 | 2.01 Bn |
| Jun 30, 2023 | 1.90 Bn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 1.83 Bn |
| Jun 30, 2022 | 1.73 Bn |
| Mar 31, 2022 | -6.61 Bn |
| Dec 31, 2021 | 4.16 Mn |
| Sep 30, 2021 | 1.39 Bn |
| Jun 30, 2021 | 1.32 Bn |
| Mar 31, 2021 | 1.07 Bn |
| Dec 31, 2020 | 982.82 Mn |
| Sep 30, 2020 | 932.36 Mn |
| Dec 31, 2019 | 300.86 Mn |